Bristol Myers Squibb’s Zeposia and Biogen’s Vumerity Place Competitive Pressure on Established Brands in the Multiple Sclerosis Switch Segment, According to Spherix Global Insights
While early patterns suggest that Genentech’s Ocrevus largely evades newcomer Novartis’ Kesimpta, COVID-19-related shifts in prescribing may be the real concern for the brand EXTON, Pa., March 31, 2021/PRNewswire/ — Biogen’s Tecfidera, Novartis’ Gilenya, and Genentech’s Ocrevus have all faced extensive competitive pressure over the past year due to launches of generics and new brands […]
Upcoming Oral, Small Molecule Agents Have the Potential to Leapfrog Existing Biologic Treatment and Become Foundational Inflammatory Bowel Disease Therapies
Six pipeline product profiles were evaluated by current inflammatory bowel disease treaters to assess strengths, weaknesses, and potential prescribing levels in the context of the current treatment algorithm EXTON, Pa., March 24, 2021 /PRNewswire/ — Spherix recently surveyed 100 US gastroenterologists and followed up with seven qualitative interviews (including an industry key opinion leader) in order to […]
Groundbreaking New Research from Spherix Global Insights Leverages More Than 1,100 Patient Charts to Provide Insights on IgA Nephropathy, Focal Segmental Glomerulosclerosis, and Alport Syndrome
Spherix announces the release of three new research publications in its RealWorld Dynamix™ series, revealing patient types, treatment paradigms, and unmet needs within IgAN, FSGS, and Alport Syndrome EXTON, Pa., March 22, 2021 /PRNewswire/ — Glomerular diseases, including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, among others, together amount to the third […]
On the Heels of Recent FDA Approvals, GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) Emerge as Practical and Effective Tools in the Treatment of Lupus Nephritis
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with the drugs EXTON, Pa., March 12, 2021 /PRNewswire/ — The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.[1] As many as half of the […]
As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve – If at All?
According to new research published by Spherix Global Insights, the CKD non-dialysis market is poised for seismic shifts as SGLT2 inhibitors, including Invokana (Vifor (Relypsa)/Janssen), Farxiga (AstraZeneca), Jardiance (Eli Lilly/Boehringer Ingelheim), and Steglatro (Merck) embrace an expanded role in diabetic nephropathy and CKD patient care in 2021 EXTON, Pa., / March 4, 2021 / PRNewswire […]
Tides Continue to Shift as Novartis’ Cosentyx and Eli Lilly’s Taltz Experience Early Success in Non-Radiographic Axial Spondyloarthritis
Managed care decisions will likely have a substantial impact on shaping rheumatologists’ future IL-17 preference, according to Spherix Global Insights EXTON, Pa., February 17, 2021 /PRNewswire/ — Approved just two weeks apart in June of last year for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA), in-class competitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, have since […]
Spherix Global Insights Releases 2020 Corporate Highlights and Shares Outlook for 2021
Company continues to post strong growth despite pandemic distraction EXTON, Pa., February 16, 2021 /PRNewswire/ — Spherix Global Insights (“Spherix”) is a hyper-focused market intelligence firm that leverages its own independent data and expertise to provide strategic guidance, which ensures biopharma stakeholders make decisions with confidence. The company focuses exclusively on select, evolving therapy areas […]
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry, particularly when it comes to in-person promotion EXTON, Pa., February 12, 2021 /PRNewswire/ — Ten months after the doors closed in response to the COVID-19 pandemic, a survey of 266 US specialty physicians conducted by Spherix Global […]
Biogen’s Vumerity and Bristol Myers Squibb’s Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents
According to Spherix Global Insights, the emerging Bruton’s tyrosine kinase inhibitors, including EMD Serono’s evobrutinib, Sanofi Genzyme’s tolebrutinib, and Genentech’s fenebrutinib, may disrupt current first-line treatment patterns, particularly in progressive multiple sclerosis EXTON, Pa., February 11, 2021/PRNewswire/ —With the recent additions of Novartis’ Mayzent, Bristol Myers Squibb’s Zeposia, and Biogen’s Vumerity to the multiple sclerosis […]
Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla than biologics or JAK inhibitors since the pandemic began in March 2020. Will that growth prevail as pandemic pressures ease? EXTON, Pa., February 10, 2021 /PRNewswire/ — Despite the potential for setbacks brought forth by the COVID-19 […]